8-K: Trevi Therapeutics Halts At-The-Market Stock Sales Program Prospectus

Trevi Therapeutics, Inc. has terminated the prospectus for its at-the-market (ATM) offering program with Leerink Partners, effectively pausing immediate common stock sales, though the underlying sales agreement remains active.

Summary

• Trevi Therapeutics, Inc. (the "Company") notified Leerink Partners LLC on June 2, 2025, of its decision to terminate the prospectus, dated August 15, 2023, related to its at-the-market (ATM) offering program.
• The termination means the Company will not make any further sales of its common stock under the existing Sales Agreement with Leerink Partners unless and until a new prospectus is filed.
• The Sales Agreement, originally entered into on June 29, 2023, remains in full force and effect.
• As of March 31, 2025, Trevi Therapeutics had issued and sold 4,498,065 shares of its common stock under this ATM program.
• These sales generated gross proceeds of approximately $14.6 million, before deducting estimated commissions and allocated fees of $0.5 million.
• No shares of common stock have been issued or sold under the Sales Agreement subsequent to March 31, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the immediate ability to raise capital via the ATM is paused, the underlying agreement remains, offering future flexibility. The action itself is procedural and doesn't inherently indicate financial distress or exceptional performance.

Positives

• The underlying Sales Agreement with Leerink Partners remains in full force and effect, allowing the Company to potentially resume ATM sales in the future by filing a new prospectus, maintaining flexibility for capital raising.

Negatives

• The termination of the current prospectus means Trevi Therapeutics cannot immediately sell additional shares of its common stock under the existing ATM program without filing a new prospectus, potentially limiting immediate access to capital through this mechanism.

Risks

• The Company's ability to raise capital quickly through an ATM offering is temporarily suspended until a new prospectus is filed, which could impact liquidity or funding for operations if immediate capital is required.
• Future capital raises via an ATM program would be subject to market conditions and the regulatory process of filing a new prospectus.

Future Outlook

The Company will not make any sales of its Common Stock pursuant to the Sales Agreement unless and until a new prospectus is filed. The Sales Agreement itself remains active, indicating a potential for future ATM offerings once a new prospectus is in place.

Management Comments

• The report was signed by Lisa Delfini, Chief Financial Officer of Trevi Therapeutics, Inc., indicating official corporate action.

Industry Context

At-the-market (ATM) offerings are a common and flexible capital raising tool for biotechnology and pharmaceutical companies like Trevi Therapeutics, allowing them to raise funds incrementally based on market conditions. The termination of a prospectus, while pausing immediate sales, is not uncommon and can be influenced by current capital needs, stock price performance, or strategic financing decisions. Companies often maintain the underlying sales agreement to retain the option for future ATM programs.

Stakeholder Impact

• Shareholders: The termination of the prospectus means no immediate dilution from this specific ATM program, but also removes a flexible capital raising option for the company in the short term. Future capital raises would depend on a new prospectus filing.
• Investors: Provides clarity on the company's current capital raising strategy, indicating a pause in ATM sales.

Next Steps

• If Trevi Therapeutics wishes to resume sales of its common stock under the Sales Agreement, it will need to file a new prospectus with the SEC.

Key Dates

Keywords

Trevi Therapeutics, ATM offering, at-the-market, common stock, capital raise, Leerink Partners, SEC filing, 8-K, equity financing, prospectus termination